Key Takeaways:
- Abbott Laboratories sees a significant stock price increase despite tariff impacts.
- Analyst predictions suggest a modest upside potential for ABT shares.
- GuruFocus values indicate a potential downside based on fair value estimates.
Abbott Laboratories (NYSE: ABT) saw its stock climb nearly 5%, marking its most notable rise in almost two years. This boost comes after the company reaffirmed its full-year earnings forecast, even as it braces for a major tariff impact. In a strategic move to counter potential new tariffs, Abbott is channeling $500 million into bolstering its U.S. manufacturing and R&D capabilities.
Wall Street Analysts' Price Targets
Wall Street analysts have set their sights on Abbott Laboratories' future, with 24 experts providing one-year price targets. The average target is pegged at $136.76, with projections as high as $158.00 and as low as $111.34. Currently, this average target hints at a potential upside of 2.25% from the recent price of $133.76. For a deeper dive into these estimates, visit our detailed Abbott Laboratories (ABT, Financial) Forecast page.
Brokerage Recommendations
An analysis of 28 brokerage firms reveals an average brokerage recommendation of 2.0 for Abbott Laboratories, indicating an "Outperform" status. This rating system ranges from 1, reflecting a Strong Buy, to 5, which signifies a Sell.
GuruFocus Estimated GF Value
The GF Value for Abbott Laboratories is estimated at $118.41 for the upcoming year, suggesting an 11.48% downside from the current stock price of $133.76. This valuation metric, developed by GuruFocus, is based on historical trading multiples, past business growth, and anticipated future performance. For additional insights, explore the comprehensive data on our Abbott Laboratories (ABT, Financial) Summary page.
